Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 15/20 | 0.68 |
| ▸ | SOAT2 | O75908 | 3/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.46 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410967 | 0.90 | DGAT1 (0.83) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL410968 | 0.90 | DGAT1 (0.83) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL10198278 | 0.90 | DGAT1 (0.69) | DGAT1SOAT2HTR2AHTR2CCYP2C9 | |
| SCHEMBL10198272 | 0.90 | DGAT1 (0.68) | DGAT1SOAT2PTPN11HTR2AHTR2C | |
| SCHEMBL10198271 | 0.90 | DGAT1 (0.82) | DGAT1SOAT2HTR2AHTR2CCYP2C9 | |
| SCHEMBL10198266 | 0.90 | DGAT1 (0.68) | DGAT1SOAT2PTPN11HTR2AHTR2C | |
| SCHEMBL10198285 | 0.87 | DGAT1 (0.65) | DGAT1SOAT2HTR2AHTR2CCYP2C9 | |
| SCHEMBL10198264 | 0.87 | DGAT1 (0.64) | DGAT1SOAT2HTR2AHTR2CCYP2C9 | |
| SCHEMBL10198301 | 0.85 | DGAT1 (0.69) | DGAT1SOAT2HTR2AHTR2CCYP2C9 | |
| SCHEMBL10198286 | 0.85 | DGAT1 (0.64) | DGAT1SOAT2PTPN11HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | DGAT1 2/4885SOAT2 9/4885PTPN11 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.